All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2026-07-24.
From the record
Standard BioTools Inc.'s filings since 2017 show 3 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2026-07-24); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2025-08-12) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-2.2% a year over 10 filed years; profitable in 0 of 10.
From the record
Standard BioTools Inc.'s 10 filed years say what it did: revenue went from $104 million in fiscal 2016 to $85 million in fiscal 2025, down 2.2% a year; it rose in 4 of 9 years; the deepest fall was 38% from fiscal 2020 to fiscal 2025; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 1.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Standard BioTools Inc.'s shareholder treatment is put at 1.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 12% of 21 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -18%: lost 18¢ per shareholder dollar. Leverage 25%: owes 25¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Standard BioTools Inc. lost about 18 cents for every dollar of shareholders' money, and gross profitability: its products earned about 7 cents per dollar of everything the company owns. Leverage: it owed about 25 cents per dollar of assets, and net share issuance: its share count grew 8.0% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 30% of 21 in its family; net margin -87.8%.
From the record
Standard BioTools Inc.'s standing among 21 graded names in its industry family: revenue of $85 million in fiscal 2025 ranks in the bottom 36% by size; a net margin of -87.8% ranks in the bottom 36%; revenue growth of -4.5% a year over the last 3 filed years ranks in the bottom 18% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 21% of 21 in its family for leadership; chief executive since 2022.
From the record
Standard BioTools Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Egholm, Michael (President & CEO, as filed), filing under that title since the record of its people begins (2022-04-04), so the years before are not on the record and this part is not read; the 9 officers and directors filing in the last fifteen months have been on the record a median of 3.7 years (bottom 36%); 13 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 7%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 49% of 21 in its family for room to expand.
From the record
Standard BioTools Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $121 million against no long-term debt tagged leaves 21.3% of its assets as net cash, top 25% of its family; cash from operations less capital spending is -96.9% of revenue (bottom 21%); a gross margin of 49.9% (bottom 42%); research spending of 30.5% of revenue (top 42%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 49% of 21 in its family for growth drivers.
From the record
Standard BioTools Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -4.5% a year over the last three filed years against -2.2% over all 10, slowing (top 27% of its family); the newest year grew -6.2% (bottom 21%); research spending grew -11.4% a year (bottom 13%); capital spending grew 29.5% a year (top 2%) (its annual reports). Standard BioTools Inc. reported 3 product lines in fiscal 2025: Consumables at $36 million (43%), Instruments at $25 million (30%), Services and Other Revenue at $24 million (28%); 1 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 36% of 20 in its family for expectations against reality.
From the record
Standard BioTools Inc.'s newest year against its own record: revenue of $85 million in fiscal 2025 came in 2.7% below the $88 million its prior three years' pace pointed to (top 47% of its family); net income of $75 million against a prior three-year average of $135 million (top 27%); a net margin of -87.8% against losses larger than its revenue before (top 32%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made